{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:42:39Z","timestamp":1791268959177,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.001","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T11:08:17Z","timestamp":1364209697000},"page":"918-923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4"],"prefix":"10.1016","volume":"12","author":[{"given":"Jan J.G.M.","family":"Verschuuren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje G.","family":"Huijbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap J.","family":"Plomp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik H.","family":"Niks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Molenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Martinez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro M.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc H.","family":"De Baets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Losen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0005","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0010","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","article-title":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","volume":"12","author":"Mori","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0015","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.autrev.2013.03.004","article-title":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","volume":"12","author":"Evoli","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.001_bb0020","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11910-011-0234-7","article-title":"Congenital myasthenic syndromes in 2012","volume":"12","author":"Engel","year":"2012","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2013.03.001_bb0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1375\/twin.14.2.129","article-title":"Utilizing twins concordance rates to infer the predisposition to myasthenia gravis","volume":"14","author":"Ramanujam","year":"2011","journal-title":"Twin Res Hum Genet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0030","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1212\/01.wnl.0000312514.66164.88","article-title":"Familial occurrence of autoimmune myasthenia gravis with different antibody specificity","volume":"70","author":"Lavrnic","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/jnnp.58.6.729","article-title":"Familial autoimmune myasthenia gravis: report of four families","volume":"58","author":"Evoli","year":"1995","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0040","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/jnnp.51.9.1228","article-title":"Familial autoimmune myasthenia gravis with different pathogenetic antibodies","volume":"51","author":"Provenzano","year":"1988","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1212\/WNL.44.3_Part_1.551","article-title":"Familial autoimmune myasthenia gravis","volume":"44","author":"Bergoffen","year":"1994","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0050","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.autrev.2013.03.003","article-title":"Complement Associated Pathogenic Mechanisms in Myasthenia Gravis","volume":"12","author":"T\u00fcz\u00fcn","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.001_bb0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis \u2014 pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.001_bb0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/intimm\/dxg088","article-title":"Spontaneous production of anti-IFN-alpha and anti-IL-12 autoantibodies by thymoma cells from myasthenia gravis patients suggests autoimmunization in the tumor","volume":"15","author":"Shiono","year":"2003","journal-title":"Int Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0065","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","volume":"43","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.001_bb0070","first-page":"55","article-title":"A histologic reappraisal of the thymus in myasthenia gravis. A correlative study of thymic pathology and response to thymectomy","volume":"91","author":"Alpert","year":"1971","journal-title":"Arch Pathol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1046\/j.1468-1331.1998.540401.x","article-title":"The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis","volume":"5","author":"Myking","year":"1998","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0080","doi-asserted-by":"crossref","first-page":"e36603","DOI":"10.1371\/journal.pone.0036603","article-title":"Late onset myasthenia gravis is associated with HLA DRB1*15:01 in the Norwegian population","volume":"7","author":"Maniaol","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0085","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.autrev.2013.03.010","article-title":"Etiology of myasthenia gravis: innate immunity signature in pathological thymus","volume":"12","author":"Cavalcante","year":"2013","journal-title":"Autoimmun Rev"},{"issue":"9","key":"10.1016\/j.autrev.2013.03.001_bb0090","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.001_bb0095","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/14737175.9.3.351","article-title":"Autoimmune myasthenia gravis","volume":"9","author":"Gilhus","year":"2009","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2013.03.001_bb0100","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0105","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0404.2005.00374.x","article-title":"Myasthenia gravis: clinical, immunological, and therapeutic advances","volume":"111","author":"Romi","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.autrev.2013.03.001_bb0110","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1212\/WNL.31.8.935","article-title":"Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology","volume":"31","author":"Scadding","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0120","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0896-8411(91)90018-8","article-title":"Anti-acetylcholine receptor antibodies decrease after thymectomy in patients with myasthenia gravis. Clinical correlations","volume":"4","author":"Kuks","year":"1991","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2013.03.001_bb0125","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.4049\/jimmunol.145.7.2115","article-title":"Thymic B cells from myasthenia gravis patients are activated B cells. Phenotypic and functional analysis","volume":"145","author":"Leprince","year":"1990","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0130","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1212\/WNL.43.5.977","article-title":"Acetylcholine receptor antibodies in juvenile myasthenia gravis","volume":"43","author":"Andrews","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0135","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1212\/WNL.44.7.1208","article-title":"Race, sex, and puberty influence onset, severity, and outcome in juvenile myasthenia gravis","volume":"44","author":"Andrews","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0140","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1212\/WNL.37.12.1854","article-title":"Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians","volume":"37","author":"Chiu","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/ana.410100506","article-title":"Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations","volume":"10","author":"Tindall","year":"1981","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0150","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1749-6632.1981.tb33741.x","article-title":"Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer","volume":"377","author":"Tindall","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF00839214","article-title":"Immunoglobulin heavy chain gene associations in myasthenia gravis: new evidence for disease heterogeneity","volume":"239","author":"Demaine","year":"1992","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0022-510X(83)90096-5","article-title":"Anti-acetylcholine receptor antibodies in myasthenia gravis. Part 2. Clinical and serological follow-up of individual patients","volume":"58","author":"Oosterhuis","year":"1983","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0170","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"Rodgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0175","first-page":"257","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. I. Patients with generalized myasthenia or disease restricted to ocular muscles","volume":"49","author":"Vincent","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0180","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0165-5728(81)90015-1","article-title":"Binding properties and subclass distribution of anti-acetylcholine receptor antibodies in myasthenia gravis","volume":"1","author":"Lefvert","year":"1981","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0185","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1136\/jnnp.41.5.394","article-title":"Determination of acetylcholine receptor antibody in myasthenia gravis: clinical usefulness and pathogenetic implications","volume":"41","author":"Lefvert","year":"1978","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0195","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/jnnp.43.7.590","article-title":"Anti-acetylcholine receptor antibodies","volume":"43","author":"Vincent","year":"1980","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/mus.880160807","article-title":"Effect of myasthenic IgG on degradation of junctional acetylcholine receptor","volume":"16","author":"Takeo","year":"1993","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.001_bb0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0140-6736(79)90823-7","article-title":"Long-term effects of repeated plasma exchange in myasthenia gravis","volume":"1","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0210","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/S0140-6736(79)92081-6","article-title":"Combined plasma exchange and immunosuppression in myasthenia gravis","volume":"2","author":"Newsom-Davis","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0215","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2008.05.029","article-title":"Immunosuppression of experimental autoimmune myasthenia gravis by mycophenolate mofetil","volume":"201\u2013202","author":"Janssen","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0220","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.001_bb0225","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.001_bb0230","first-page":"267","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.autrev.2013.03.001_bb0235","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0240","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1002\/eji.1830220939","article-title":"Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor","volume":"22","author":"Loutrari","year":"1992","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0245","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1196\/annals.1405.034","article-title":"Treatment of myasthenia gravis by preventing acetylcholine receptor modulation","volume":"1132","author":"Losen","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0250","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1073\/pnas.74.7.3090","article-title":"Modulation of acetylcholine receptor by antibody against the receptor","volume":"74","author":"Heinemann","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2013.03.001_bb0255","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.001_bb0260","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1073\/pnas.80.13.4089","article-title":"Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia","volume":"80","author":"Gomez","year":"1983","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2013.03.001_bb0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"Almon","year":"1974","journal-title":"Science"},{"key":"10.1016\/j.autrev.2013.03.001_bb0270","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-5728(86)90098-6","article-title":"Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis","volume":"12","author":"Vernet-der Garabedian","year":"1986","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-5728(83)90022-X","article-title":"Acetylcholine receptor antibody characteristics in myasthenia gravis. Fractionation of alpha-bungarotoxin binding site antibodies and their relationship to IgG subclass","volume":"5","author":"Whiting","year":"1983","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0280","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/clinchem\/39.10.2053","article-title":"Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis","volume":"39","author":"Hara","year":"1993","journal-title":"Clin Chem"},{"key":"10.1016\/j.autrev.2013.03.001_bb0285","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0165-5728(88)90043-4","article-title":"Plasma from myasthenia gravis patients reduces acetylcholine receptor agonist-induced Na+flux into TE671 cell line","volume":"19","author":"Lang","year":"1988","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0290","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ana.410440412","article-title":"Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel","volume":"44","author":"Wintzen","year":"1998","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0295","doi-asserted-by":"crossref","first-page":"644","DOI":"10.2353\/ajpath.2007.060676","article-title":"Overexpression of rapsyn in rat muscle increases acetylcholine receptor levels in chronic experimental autoimmune myasthenia gravis","volume":"170","author":"Martinez-Martinez","year":"2007","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s004010050483","article-title":"Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis","volume":"92","author":"Ito","year":"1996","journal-title":"Acta Neuropathol"},{"issue":"Pt 9","key":"10.1016\/j.autrev.2013.03.001_bb0305","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/brain\/120.9.1513","article-title":"Utrophin abundance is reduced at neuromuscular junctions of patients with both inherited and acquired acetylcholine receptor deficiencies","volume":"120","author":"Slater","year":"1997","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.001_bb0310","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1093\/brain\/awh612","article-title":"Increased expression of rapsyn in muscles prevents acetylcholine receptor loss in experimental autoimmune myasthenia gravis","volume":"128","author":"Losen","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.001_bb0315","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.nbd.2009.03.008","article-title":"Silencing rapsyn in vivo decreases acetylcholine receptors and augments sodium channels and secondary postsynaptic membrane folding","volume":"35","author":"Martinez-Martinez","year":"2009","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.autrev.2013.03.001_bb0320","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1196\/annals.1254.033","article-title":"Immunoregulation in experimental autoimmune myasthenia gravis \u2014 about T cells, antibodies, and endplates","volume":"998","author":"De Baets","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0325","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1172\/JCI117302","article-title":"Regulation of acetylcholine receptor alpha subunit variants in human myasthenia gravis. Quantification of steady-state levels of messenger RNA in muscle biopsy using the polymerase chain reaction","volume":"94","author":"Guyon","year":"1994","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2013.03.001_bb0330","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1749-6632.1998.tb10953.x","article-title":"Respective role of thymus and muscle in autoimmune myasthenia gravis","volume":"841","author":"Moulian","year":"1998","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0335","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1098\/rspb.1976.0025","article-title":"Acetylcholine in human muscle","volume":"192","author":"Ito","year":"1976","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0340","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1111\/j.1471-4159.1981.tb04657.x","article-title":"Choline acetyltransferase in skeletal muscle from patients with myasthenia gravis","volume":"37","author":"Molenaar","year":"1981","journal-title":"J Neurochem"},{"key":"10.1016\/j.autrev.2013.03.001_bb0345","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0079-6123(08)64657-9","article-title":"Acetylcholine in intercostal muscle from myasthenia gravis patients and in rat diaphragm after blockade of acetylcholine receptors","volume":"49","author":"Molenaar","year":"1979","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.autrev.2013.03.001_bb0350","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1113\/jphysiol.1980.sp013145","article-title":"On the release of transmitter at normal, myasthenia gravis and myasthenic syndrome affected human end-plates","volume":"299","author":"Cull-Candy","year":"1980","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0355","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/ana.410370513","article-title":"Acetylcholine release in myasthenia gravis: regulation at single end-plate level","volume":"37","author":"Plomp","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0360","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/272641a0","article-title":"Alpha-Bungarotoxin enhances transmitter \u201creleased\u201d at the neuromuscular junction","volume":"272","author":"Miledi","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.001_bb0365","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1136\/jnnp-2012-302705","article-title":"Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis","volume":"83","author":"Masuda","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0370","doi-asserted-by":"crossref","first-page":"13898","DOI":"10.1523\/JNEUROSCI.2833-09.2009","article-title":"Main immunogenic region structure promotes binding of conformation-dependent myasthenia gravis autoantibodies, nicotinic acetylcholine receptor conformation maturation, and agonist sensitivity","volume":"29","author":"Luo","year":"2009","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0375","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/08916930903518073","article-title":"The auto-antigen repertoire in myasthenia gravis","volume":"43","author":"Vrolix","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.001_bb0380","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3109\/08916930903555935","article-title":"Thymoma and paraneoplastic myasthenia gravis","volume":"43","author":"Marx","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.001_bb0385","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/S0140-6736(86)92259-2","article-title":"Myasthenia gravis without acetylcholine-receptor antibody: a distinct disease entity","volume":"1","author":"Mossman","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0390","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1002\/mus.880171208","article-title":"Passive transfer of seronegative myasthenia gravis to mice","volume":"17","author":"Burges","year":"1994","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.001_bb0395","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1196\/annals.1405.020","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibodies","volume":"1132","author":"Vincent","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.001_bb0400","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.autrev.2013.03.001_bb0405","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.001_bb0410","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0415","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00415-011-6194-7","article-title":"Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis","volume":"259","author":"Pevzner","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0420","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0425","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.001_bb0430","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.001_bb0435","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.001_bb0440","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0450","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low-dose rituximab is effective in pemphigus","volume":"166","author":"Horvath","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0455","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1073\/pnas.92.11.5239","article-title":"Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity","volume":"92","author":"Bhol","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2013.03.001_bb0460","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0465","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0470","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14-DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0475","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0480","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2222.2009.03207.x","article-title":"Immunoglobulin G4: an odd antibody","volume":"39","author":"Aalberse","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.autrev.2013.03.001_bb0485","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","article-title":"Structure and function of immunoglobulins","volume":"125","author":"Schroeder","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0490","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.molimm.2011.04.024","article-title":"Complement activation by (auto-) antibodies","volume":"48","author":"Daha","year":"2011","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0495","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","article-title":"IgG4 breaking the rules","volume":"105","author":"Aalberse","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-007-0734-0","article-title":"The relevance of the IgG subclass of autoantibodies for blister induction in autoimmune bullous skin diseases","volume":"299","author":"Sitaru","year":"2007","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.autrev.2013.03.001_bb0505","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.001_bb0510","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/j.1538-7836.2009.03568.x","article-title":"IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura","volume":"7","author":"Ferrari","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.autrev.2013.03.001_bb0515","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1056\/NEJM198906013202206","article-title":"The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem)","volume":"320","author":"Rock","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2013.03.001_bb0520","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.WNL.0000129702.41868.A5","article-title":"Is \u201cseronegative\u201d MG explained by autoantibodies to MuSK?","volume":"62","author":"Lindstrom","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0525","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1212\/01.WNL.0000128048.23930.1D","article-title":"Are MuSK antibodies the primary cause of myasthenic symptoms?","volume":"62","author":"Selcen","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0530","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/ana.20341","article-title":"Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis","volume":"57","author":"Shiraishi","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0535","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1002\/ana.21371","article-title":"Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction","volume":"63","author":"Cole","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0540","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.2353\/ajpath.2009.090040","article-title":"The effect of plasma from muscle-specific tyrosine kinase myasthenia patients on regenerating endplates","volume":"175","author":"ter Beek","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0545","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1113\/jphysiol.2010.190298","article-title":"Patient autoantibodies deplete postsynaptic muscle-specific kinase leading to disassembly of the ACh receptor scaffold and myasthenia gravis in mice","volume":"588","author":"Cole","year":"2010","journal-title":"J Physiol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0550","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.001_bb0555","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1093\/brain\/aws025","article-title":"Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice","volume":"135","author":"Klooster","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.001_bb0560","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.expneurol.2012.01.025","article-title":"Passive and active immunization models of MuSK-Ab positive myasthenia: electrophysiological evidence for pre and postsynaptic defects","volume":"234","author":"Viegas","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0565","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.expneurol.2012.06.034","article-title":"Muscle specific kinase autoantibodies cause synaptic failure through progressive wastage of postsynaptic acetylcholine receptors","volume":"237","author":"Morsch","year":"2012","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0570","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0575","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cell.2008.10.002","article-title":"Lrp4 is a receptor for Agrin and forms a complex with MuSK","volume":"135","author":"Kim","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2013.03.001_bb0580","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/nature11348","article-title":"Lrp4 is a retrograde signal for presynaptic differentiation at neuromuscular synapses","volume":"489","author":"Yumoto","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2013.03.001_bb0585","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.conb.2005.12.003","article-title":"Assembly of the postsynaptic membrane at the neuromuscular junction: paradigm lost","volume":"16","author":"Kummer","year":"2006","journal-title":"Curr Opin Neurobiol"},{"key":"10.1016\/j.autrev.2013.03.001_bb0590","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajhg.2009.06.015","article-title":"Identification of an agrin mutation that causes congenital myasthenia and affects synapse function","volume":"85","author":"Huze","year":"2009","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.autrev.2013.03.001_bb0595","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0092-8674(00)81253-2","article-title":"Defective neuromuscular synaptogenesis in agrin-deficient mutant mice","volume":"85","author":"Gautam","year":"1996","journal-title":"Cell"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721300027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721300027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T10:03:53Z","timestamp":1688119433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721300027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":118,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S156899721300027X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727884532.793552104","asserted-by":"object"}]},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}